原发性肝神经内分泌瘤1例报告

杜季康; 赵小玲; 杨贵彬; 魏武; 脱红芳

doi:10.3969/j.issn.1001-5256.2021.06.043

原发性肝神经内分泌瘤1例报告

DOI: 10.3969/j.issn.1001-5256.2021.06.043

杜季康^{1, 2a},
赵小玲^{1, 2b},
杨贵彬^{1, 2a},
魏武^{1, 2a},
脱红芳^2a, ,

1.
华北理工大学研究生学院，河北唐山 063210
2a.
河北省人民医院肝胆胰脾外科，石家庄 050051
2b.
河北省人民医院消化内科，石家庄 050051

利益贡献声明：所有作者均声明不存在利益冲突。

作者贡献声明：杜季康、赵小玲负责课题设计，资料分析，撰写论文；杜季康、杨贵彬、魏武参与收集数据，修改论文；脱红芳负责拟定写作思路，指导撰写文章并最后定稿。

详细信息

作者简介:
杜季康(1993—)，男，主要从事肝胆疾病研究

通信作者:
脱红芳，touhf@aliyun.com

中图分类号: R735.7
计量
- 文章访问数: 339
- HTML全文浏览量: 238
- PDF下载量: 34
- 被引次数: 0
出版历程
- 收稿日期: 2020-11-18
- 录用日期: 2020-12-10
- 出版日期: 2021-06-20

A case of primary hepatic neuroendocrine tumor

Jikang DU^{1, 2a},
Xiaoling ZHAO^{1, 2b},
Guibin YANG^{1, 2a},
Wu WEI^{1, 2a},
Hongfang TUO^{2a
, ,}

1.
Graduate School, North China University of Science and Technology, Tangshan, Hebei 063210, China
2a.
Department of Hepatobiliary, Hebei General Hospital, Shijiazhuang 050051, China
2b.
Department of Gastroenterology, Hebei General Hospital, Shijiazhuang 050051, China

摘要

- 肝肿瘤 /
- 神经内分泌瘤 /
- 化学栓塞, 治疗性
- Liver Neoplasms /
- Neuroendocrine Tumors /
- Chemoembolization, Therapeutic

HTML全文

图 1 TACE治疗前腹部增强MRI检查结果

注：a, DWI示多个高信号影；b, 动脉期最大病灶不均匀明显强化；c, 静脉期呈持续性不均匀强化，强化程度略减低。

下载: 全尺寸图片幻灯片

图 2 病理及免疫组化结果

注：a, 病理检查符合肝神经内分泌瘤(HE染色，×100)；b, 免疫组化示Syn阳性(×100)；c, 免疫组化示CgA阳性(×100)。

下载: 全尺寸图片幻灯片

图 3 TACE治疗前后腹部增强MRI对比(动脉期)

注：a, TACE治疗前最大病灶强化；b, 经3次TACE治疗后最大病灶明显缩小，甚至消失。

下载: 全尺寸图片幻灯片

表 1 2019年第5版世界卫生组织消化系统NEN分级

NEN分级	核分裂像(/10HPF)	Ki-67阳性指数(%)
G1，低级别	＜2	＜3
G2，中级别	2~20	3~20
G3，高级别	＞20	＞20

下载: 导出CSV

参考文献(17)

[1]	CAMARGO ÉS, VIVEIROS MDE M, CORRÊA NETO IJ, et al. Primary hepatic carcinoid tumor: Case report and literature review[J]. Einstein (Sao Paulo), 2014, 12(4): 505-508. DOI: 10.1590/S1679-45082014RC2745.
[2]	PATHAK S, DASH I, TAYLOR MR, et al. The surgical management of neuroendocrine tumour hepatic metastases[J]. Eur J Surg Oncol, 2013, 39(3): 224-228. DOI: 10.1016/j.ejso.2012.12.001.
[3]	NAGTEGAAL ID, ODZE RD, KLIMSTRA D, et al. The 2019 WHO classification of tumours of the digestive system[J]. Histopathology, 2020, 76(2): 182-188. DOI: 10.1111/his.13975.
[4]	TAO L, XIU D, SADULA A, et al. Surgical resection of primary tumor improves survival of pancreatic neuroendocrine tumor with liver metastases[J]. Oncotarget, 2017, 8(45): 79785-79792. DOI: 10.18632/oncotarget.19523.
[5]	WANG B, YAO DY, XU X, et al. Primary hepatic neuroendocrine tumor: Two case report[J]. Chin J Clin Exp Pathol, 2019, 35(4): 503-504. DOI: 10.13315/j.cnki.cjcep.2019.04.039. 王博, 姚冬颖, 许欣, 等. 肝脏原发性神经内分泌瘤2例[J]. 临床与实验病理学杂志, 2019, 35(4): 503-504. DOI: 10.13315/j.cnki.cjcep.2019.04.039.
[6]	ORTIZ J, BALASUBRAMANIAN M, BROWN T, et al. Liver transplant for neuroendocrine tumor metastatic to the liver: Literature review and report of extirpation at 16-year recurrence[J]. Exp Clin Transplant, 2015, 13(1): 86-91. DOI: 10.6002/ect.2013.0215.
[7]	LING JK, WANG M, YUAN J, et al. CT and MRI findings of primary hepatic neuroendocrine neoplasm[J]. Chin J Oncol, 2017, 39(8): 600-606. DOI: 10.3760/cma.j.issn.0253-3766.2017.08.008. 李家开, 王敏, 袁静, 等. 肝脏原发性神经内分泌肿瘤的CT和磁共振成像表现[J]. 中华肿瘤杂志, 2017, 39(8): 600-606. DOI: 10.3760/cma.j.issn.0253-3766.2017.08.008.
[8]	KULKE MH, SHAH MH, BENSON AB 3rd, et al. Neuroendocrine tumors, version 1.2015[J]. J Natl Compr Canc Netw, 2015, 13(1): 78-108. DOI: 10.6004/jnccn.2015.0011.
[9]	GAO WH, XIANG XX. Primary hepatic neuroendocrine neoplasm: A report of 2 cases and literature review[J]. J Clin Hepatol, 2017, 33(6): 1149-1151. DOI: 10.3969/j.issn.1001-5256.2017.06.028. 高伟华, 向晓星. 原发性肝脏神经内分泌肿瘤2例报告并文献复习[J]. 临床肝胆病杂志, 2017, 33(6): 1149-1151. DOI: 10.3969/j.issn.1001-5256.2017.06.028.
[10]	WEI RG, ZHOU Z, WU HR, et al. Diagnosis and treatment experience of primary hepatic neuroendocrine neoplasm[J/CD]. Chin J Hepat Surg(Electronic Edition), 2018, 7(3): 216-220. DOI: 10.3877/cma.j.issn.2095-3232.2018.03.012. 魏荣光, 周舟, 吴浩然, 等. 原发性肝脏神经内分泌肿瘤诊治经验[J/CD]. 中华肝脏外科手术学电子杂志, 2018, 7(3): 216-220. DOI: 10.3877/cma.j.issn.2095-3232.2018.03.012.
[11]	HAN Y, LI L, SUN H. Computed tomography and magnetic resonance imaging in the diagnosis of primary neuroendocrine tumors of the liver[J]. World Neurosurg, 2020, 138: 723-731. DOI: 10.1016/j.wneu.2020.01.169.
[12]	AO WQ, WU D, ZENG MS, et al. CT and MRI diagnosis of primary hepatic neuroendocrine carcinoma[J]. Radiol Pract, 2013, 28(10): 1032-1036. https://www.cnki.com.cn/Article/CJFDTOTAL-FSXS201310015.htm 敖炜群, 吴东, 曾蒙苏, 等. 原发性肝脏神经内分泌癌的CT和MRI诊断[J]. 放射学实践, 2013, 28(10): 1032-1036. https://www.cnki.com.cn/Article/CJFDTOTAL-FSXS201310015.htm
[13]	WANG WQ. Comparison of contrast-enhanced ultrasonography between primary and metastatic neuroendocrine tumors of the liver[J]. Chin Hepatol, 2020, 25(5): 498-500. DOI: 10.3969/j.issn.1008-1704.2020.05.017. 王文清. 肝脏原发性和转移性神经内分泌肿瘤的超声造影表现对比[J]. 肝脏, 2020, 25(5): 498-500. DOI: 10.3969/j.issn.1008-1704.2020.05.017.
[14]	LI P, YANG XO, QIAN JM. The clinical characteristic of 43 cases of neuroendocrine tumors with liver metastases[J]. Chin J Intern Med, 2012, 51(4): 289-293. DOI: 10.3760/cma.j.issn.0578-1426.2012.04.011. 李攀, 杨晓鸥, 钱家鸣. 神经内分泌肿瘤肝转移的临床特征与诊治[J]. 中华内科杂志, 2012, 51(4): 289-293. DOI: 10.3760/cma.j.issn.0578-1426.2012.04.011.
[15]	TANER T, ATWELL TD, ZHANG L, et al. Adjunctive radiofrequency ablation of metastatic neuroendocrine cancer to the liver complements surgical resection[J]. HPB (Oxford), 2013, 15(3): 190-195. DOI: 10.1111/j.1477-2574.2012.00528.x.
[16]	LIU YW, CUI GZ, LIU XL, et al. A case of primary hepatic high-grade neuroendocrine carcinoma[J]. J Clinl Hepatol, 2020, 36(1): 161-163. DOI: 10.3969/j.issn.1001-5256.2020.01.036. 刘宇维, 崔国振, 刘相良, 等. 肝脏原发高级别神经内分泌癌1例报告[J]. 临床肝胆病杂志, 2020, 36(1): 161-163. DOI: 10.3969/j.issn.1001-5256.2020.01.036.
[17]	FOSTER DS, JENSEN R, NORTON JA. Management of liver neuroendocrine tumors in 2018[J]. JAMA Oncol, 2018, 4(11): 1605-1606. DOI: 10.1001/jamaoncol.2018.3035.